Centessa Pharmaceuticals Business Summary

Centessa Pharmaceuticals plc (CNTA) is a clinical-stage biotechnology company that operates through a unique "asset-centric" model, though it has recently pivoted to a "pure-play" strategic focus on its Orexin Receptor 2 (OX2R) agonist portfolio. The company generates revenue primarily through licensing agreements and strategic collaborations, reporting approximately $15 million in trailing twelve-month revenue as of early 2026, while remaining pre-commercial for its lead assets. Its primary business segments are organized around its clinical pipeline, led by the orexin franchise (ORX750, ORX142, and ORX489) targeting narcolepsy and idiopathic hypersomnia, alongside programs in hemophilia (SerpinPC) and immuno-oncology (LockBody platform). Centessa competes directly with Takeda (oveporexton), Alkermes (alixorexton), and Jazz Pharmaceuticals in the high-stakes sleep-disorder market; it positions itself as a potential best-in-class leader by advancing ORX750 into registrational trials in early 2026, aiming to address unmet needs in Narcolepsy Type 2 and Idiopathic Hypersomnia where competitors have historically lagged. The company was founded in 2021 by the life sciences venture firm Medicxi, led by Chairman Francesco De Rubertis, PhD, through the merger of ten private biotech startups. Effective January 1, 2026, Mario Alberto Accardi, PhD—the founder of Centessa’s Orexin Program and former CEO of Orexia Therapeutics—succeeded Saurabh Saha, MD, PhD, as Chief Executive Officer to spearhead the company's neuroscience-focused expansion. The executive leadership team includes Tia Bush as Chief Technology and Quality Officer, John Crowley as Chief Financial Officer, and Stephen Kanes, MD, PhD, as Head of R&D and Chief Medical Officer. Centessa is backed by a high-pedigree investor base including General Atlantic, Vida Ventures, and Janus Henderson Investors, with notable board representation from Brett Zbar, MD (Managing Director at General Atlantic) and Samarth Kulkarni, PhD (CEO of CRISPR Therapeutics).